Oncternal Therapeutics, Inc. (ONCT): Price and Financial Metrics


Oncternal Therapeutics, Inc. (ONCT)

Today's Latest Price: $2.90 USD

0.02 (0.69%)

Updated Jun 4 4:00pm

Add ONCT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

ONCT Stock Summary

  • For ONCT, its debt to operating expenses ratio is greater than that reported by merely 5.09% of US equities we're observing.
  • ONCT's price/sales ratio is 17.51; that's higher than the P/S ratio of 92.67% of US stocks.
  • As for revenue growth, note that ONCT's revenue has grown 107.88% over the past 12 months; that beats the revenue growth of 94.8% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Oncternal Therapeutics Inc, a group of peers worth examining would be RBBN, MUX, FF, CMRX, and ABUS.
  • Visit ONCT's SEC page to see the company's official filings. To visit the company's web site, go to www.oncternal.com.
ONCT Daily Price Range
ONCT 52-Week Price Range

ONCT Stock Price Chart More Charts


ONCT Price/Volume Stats

Current price $2.90 52-week high $9.80
Prev. close $2.88 52-week low $2.24
Day low $2.88 Volume 31,441
Day high $3.28 Avg. volume 18,891
50-day MA $2.77 Dividend yield N/A
200-day MA $4.21 Market Cap 44.64M

Oncternal Therapeutics, Inc. (ONCT) Company Bio


Oncternal Therapeutics (formerly GTx, Inc.), a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other serious medical conditions. The company was founded in 1997 and is based in Memphis, Tennessee.


ONCT Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ONCT Latest Social Stream


Loading social stream, please wait...

View Full ONCT Social Stream

Latest ONCT News From Around the Web

Below are the latest news stories about Oncternal Therapeutics Inc that investors may wish to consider to help them evaluate ONCT as an investment opportunity.

Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 1,943,636 shares of its common stock, at a purchase price of $2.5725 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Oncternal has also agreed to issue to the investors, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 971,818 shares of its common stock. The closing of the offering is expected to occur on or about May 21, 2020, subject to the satisfaction of customary closing conditions.

Yahoo | May 20, 2020

Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, in which cirmtuzumab, an investigational anti-ROR1 monoclonal antibody, is being evaluated in combination with ibrutinib in patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL). The data will be presented as part of the American Society of Clinical Oncology (ASCO) 2020 Virtual Annual Meeting, and a copy of the poster presentation will be available online at www.oncternal.com on May 29, 2020:

Yahoo | May 19, 2020

Oncternal Provides Business Update and Announces First Quarter 2020 Financial Results

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported first quarter 2020 financial results.

Yahoo | May 7, 2020

Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2020 financial results before U.S. financial markets open on Thursday, May 7, 2020. Oncternal’s management will host a webcast and conference call at 12:00 p.m. PDT (3:00 p.m. EDT) to discuss the Company’s financial results and provide a comprehensive business update. The time of the webcast has been changed due to the unusually high demand for conferencing services on this date.

Yahoo | May 5, 2020

Is Oncternal Therapeutics (NASDAQ:ONCT) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | March 18, 2020

Read More 'ONCT' Stories Here

ONCT Price Returns

1-mo 9.19%
3-mo -21.83%
6-mo -46.30%
1-year -65.48%
3-year -87.67%
5-year -96.30%
YTD -26.58%
2019 -27.66%
2018 -93.86%
2017 140.72%
2016 -24.57%
2015 -4.11%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0776 seconds.